Results of myocardial revascularization in patients with acute coronary syndrome and COVID-19: experience of the urban multidisciplinary hospital

Background. The 2019 novel coronavirus pandemic has had a significant impact on the prognosis and outcomes of patients with acute coronary syndrome (ACS).

Objective. Study of the impact of a new coronavirus infection (NCI) on the nature of the course and outcomes of the disease in patients with ACS.

Materials and methods. The study included patients with ACS and a positive test for COVID-19 upon admission to the hospital in the period from April 2020 to August 2021.

Results. The study included 107 patients. Among patients with and without ST elevation with more than 50 % lesions (n = 10; n = 10), 8 patients died, which was 80 % in each group. In the group with and without ST elevation with less than 50 % involvement (n = 20; n = 67), 5 and 8 patients died, accounting for 25 % and 11.9 %, respectively. The role of the influence of the levels of Il-6 (interleukin-6), troponin T and creatinine on the course and outcomes of the patients’ disease was analyzed.

Conclusion. COVID-19 infection, namely the degree of damage to the lung tissue, significantly worsens the course and outcomes in patients with both NSTE-ACS and STE-ACS. Further accumulation of clinical experience in endovascular treatment of ACS and the development of algorithms for providing medical care to patients with ACS in the context of COVID-19 is required.

1. Obrezan AA, Soloveva MV, Mikhailova LV, et al. Comorbidity in patients with cardiovascular disease who underwent a new coronavirus infection. Kardiologiya: novosti, mneniya, obuchenie=Cardiology: News, Opinions, Training. 2022; 10 (2): 51–56. In Russian [Обрезан А.А., Соловьева М.В., Михайлова Л.В. и др. Коморбидный пациент кардиологического профиля, перенесший новую коронавирусную инфекцию. Кардиология: новости, мнения, обучение. 2022; 2:51–56]. DOI: 10.33029/23091908-2022-10-2-51-56.

2. Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020; 46(6):1089–1098. DOI: 10.1007/s00134-020-06062-x.

3. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–147. DOI: 10.1016/j.thromres.2020.04.013.

4. Masi P, Hékimian G, Lejeune M, et al. Systemic Inflammatory Response Syndrome Is a Major Contributor to COVID-19-Associated Coagulopathy: Insights From a Prospective, Single-Center Cohort Study. Circulation. 2020; 142(6):611–614. DOI: 10.1161/CIRCULATIONAHA.120.048925.

5. Benyounes N, Van Der Vynckt C, Tibi S, et al. Echocardiography in Confirmed and Highly Suspected Symptomatic COVID-19 Patients and Its Impact on Treatment Change. Cardiol Res Pract. 2020; 2020:4348598. DOI: 10.1155/2020/4348598.

6. John K, Lal A, Sharma N, et al. Presentation and outcome of myocardial infarction with non-obstructive coronary arteries in coronavirus disease 2019. World J Crit Care Med. 2022; 11(3):129–138. DOI: 10.5492/wjccm.v11.i3.129.

7. Sala S, Peretto G, Gramegna M, et al. Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection. Eur Heart J. 2020; 41(19):1861–1862. DOI: 10.1093/eurheartj/ehaa286.

8. John K, Lal A, Mishra A. A review of the presentation and outcome of takotsubo cardiomyopathy in COVID-19. Monaldi Arch Chest Dis. 2021; 91(3). DOI: 10.4081/monaldi.2021.1710.

9. Yapan Emren Z, Emren V, Özdemir E, et al. Spontaneous right coronary artery dissection in a patient with COVID-19 infection: A case report and review of the literature. Turk Kardiyol Dern Ars. 2021; 49(4):334–338. DOI: 10.5543/tkda.2021.34846.

10. Courand PY, Harbaoui B, Bonnet M, et al. Spontaneous Coronary Artery Dissection in a Patient With COVID-19. JACC Cardiovasc Interv. 2020; 13(12):e107– e108. DOI: 10.1016/j.jcin.2020.04.006.

11. Rivero F, Antuña P, Cuesta J, et al. Severe coronary spasm in a COVID-19 patient. Catheter Cardiovasc Interv. 2021; 97(5):E670–E672. DOI: 10.1002/ccd.29056.

12. Tobler DL, Pruzansky AJ, Naderi S, et al. LongTerm Cardiovascular Effects of COVID-19: Emerging Data Relevant to the Cardiovascular Clinician. Curr Atheroscler Rep. 2022; 24(7):563–570. DOI: 10.1007/s11883-022-01032-8.

13. Fang X, Li S, Yu H, et al. Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis. Aging (Albany NY). 2020; 12(13):12493–12503. DOI: 10.18632/aging.103579.

14. Demir OM, Ryan M, Cirillo C, et al. Impact and Determinants of High-Sensitivity Cardiac Troponin-T Concentration in Patients With COVID-19 Admitted to Critical Care. Am J Cardiol. 2021; 147:129–136. DOI: 10.1016/j.amjcard.2021.01.037.

15. Chauin A. The Main Causes and Mechanisms of Increase in Cardiac Troponin Concentrations Other Than Acute Myocardial Infarction (Part 1): Physical Exertion, Inflammatory Heart Disease, Pulmonary Embolism, Renal Failure, Sepsis. Vasc Health Risk Manag. 2021; 17:601–617. DOI: 10.2147/VHRM.S327661.

16. Sandoval Y, Januzzi JL Jr, Jaffe AS. Cardiac Troponin for Assessment of Myocardial Injury in COVID-19: JACC Review Topic of the Week. J Am Coll Cardiol. 2020; 76(10):1244–1258. DOI: 10.1016/j.jacc.2020.06.068.

17. Zaki HA, Shaban AE, Shaban AE, et al. Interpretation of Cardiac and Non-Cardiac Causes of Elevated Troponin T Levels in Non-Acute Coronary Syndrome Patients in the Emergency Department. Cureus. 2022; 14(2):e22703. DOI: 10.7759/cureus.22703.

18. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054–1062. DOI: 10.1016/S01406736(20)30566-3.